WallStSmart

Agilent Technologies Inc (A)vsNovartis AG ADR (NVS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 678% more annual revenue ($57.36B vs $7.37B). A leads profitability with a 19.5% profit margin vs 17.5%. A appears more attractively valued with a PEG of 1.53. A earns a higher WallStSmart Score of 61/100 (C+).

A

Buy

61

out of 100

Grade: C+

Growth: 5.3Profit: 8.5Value: 3.3Quality: 6.0
Piotroski: 3/9Altman Z: 1.99

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-63.0%)

Margin of Safety

-63.0%

Fair Value

$79.06

Current Price

$173.01

$93.95 premium

UndervaluedFair: $79.06Overvalued
NVSSignificantly Overvalued (-69.8%)

Margin of Safety

-69.8%

Fair Value

$95.76

Current Price

$160.32

$64.56 premium

UndervaluedFair: $95.76Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Market CapQuality
$50.16B9/10

Large-cap with strong market position

Operating MarginProfitability
25.6%8/10

Strong operational efficiency at 25.6%

NVS4 strengths · Avg: 9.3/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Return on EquityProfitability
26.9%9/10

Every $100 of equity generates 27 in profit

Free Cash FlowQuality
$4.76B8/10

Generating 4.8B in free cash flow

Areas to Watch

A4 concerns · Avg: 3.8/10
PEG RatioValuation
1.534/10

Expensive relative to growth rate

P/E RatioValuation
35.5x4/10

Premium valuation, high expectations priced in

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.1x4/10

Trading at 8.1x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Market Cap, Operating Margin. Profitability is solid with margins at 19.5% and operating margin at 25.6%.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Operating Margin, Return on Equity. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bear Case : A

The primary concerns for A are PEG Ratio, P/E Ratio, Altman Z-Score.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Key Dynamics to Monitor

A profiles as a mature stock while NVS is a value play — different risk/reward profiles.

A carries more volatility with a beta of 1.24 — expect wider price swings.

A is growing revenue faster at 8.1% — sustainability is the question.

NVS generates stronger free cash flow (4.8B), providing more financial flexibility.

Bottom Line

A scores higher overall (61/100 vs 48/100), backed by strong 19.5% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?